ARYA Atherosclerosis Journal

Resistin and prooxidant-antioxidant balance: Markers to discriminate acute coronary syndrome from stable angina

Document Type : Original Article(s)

Authors

Ali Pourmoghaddas 1
Armin Elahifar 2
Faramarz Darabi 3
Ahmad Movahedian 4
Afshin Amirpour 5
Nizal Sarrafzadegan 6

1 Interventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

2 Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

3 Heart Failure Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences AND Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

5 Assistant Professor, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

6 2- Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran 6- Faculty of Medicine, School of Population and Public Health, University of British Columbia, Vancouver, Canada

https://doi.org/10.22122/arya.v16i2.1944
Abstract
BACKGROUND: Resistin and oxidative stress may play a role in the pathogenesis of coronary heart disease (CHD) including acute coronary syndrome (ACS). The aim of this study was to investigate the role of serum resistin and prooxidant-antioxidant balance (PAB) in ACS occurrence in order to differentiate it from stable angina. Moreover, we aimed to determine the correlation between resistin and PAB in patients with ACS and its difference from patients with stable CHD.METHODS: This cross-sectional, descriptive study was conducted on 50 patients with ACS and 50 patients with stable CHD who underwent coronary angiography (CAG). Serum resistin level was measured using enzyme-linked immunosorbent assay (ELISA). PAB and other variables were analyzed using standard methods.RESULTS: A significant increase in serum resistin and PAB was observed in patients with ACS (2.55 ± 0.13 ng/ml and 123.5 ± 5.58 HK unit, respectively) compared to patients with stable CHD (1.53 ± 0.12 ng/ml and 95.9 ± 2.7 HK unit, respectively) (P < 0.001). In addition, a significant positive correlation was seen between serum resistin and PAB in patients with ACS (r = 0.39; P = 0.005), but this correlation was not found in patients with stable CHD (r = 0.21; P = 0.140). Resistin (r = 0.52; P < 0.001) and PAB (r = 0.55; P < 0.001) were significantly associated with high-sensitivity C-reactive protein (hs-CRP) in patients with ACS, but this association was not found in patients with stable CHD (resistin: r = 0.24; P = 0.090; PAB: r = -0.02: P = 0.910).CONCLUSION: High serum resistin or PAB levels, and their association with the occurrence of ACS, can be used as a robust discriminating factor to differentiate ACS from stable CHD. 

Keywords

Acute Coronary Syndrome
Resistin
Antioxidants
  1. Alfieri O, Mayosi BM, Park SJ, Sarrafzadegan N, Virmani R. Exploring unknowns in cardiology. Nat Rev Cardiol 2014; 11(11): 664-70.
  2. Ozturk HS, Cimen MY, Cimen OB, Kacmaz M, Durak I. Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int 1999; 19(1-2): 35-7.
  3. Anwaruddin S, Askari AT, Topol EJ. Redefining risk in acute coronary syndromes using molecular medicine. J Am Coll Cardiol 2007; 49(3): 279-89.
  4. Ghayour-Mobarhan M, Alamdari DH, Moohebati M, Sahebkar A, Nematy M, Safarian M, et al. Determination of prooxidant--antioxidant balance after acute coronary syndrome using a rapid assay: A pilot study. Angiology 2009; 60(6): 657-62.
  5. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91(3A): 7A-11A.
  6. Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE, et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA 2014; 311(3): 271-8.
  7. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47(8 Suppl): C13-C18.
  8. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75(2): 346-59.
  9. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000; 343(13): 915-22.
  10. Meydani M. Vitamin E modulation of cardiovascular disease. Ann N Y Acad Sci 2004; 1031: 271-9.
  11. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003; 111(2): 225-30.
  12. Talman AH, Psaltis PJ, Cameron JD, Meredith IT, Seneviratne SK, Wong DT. Epicardial adipose tissue: Far more than a fat depot. Cardiovasc Diagn Ther 2014; 4(6): 416-29.
  13. Qiao XZ, Yang YM, Xu ZR, Yang LA. Relationship between resistin level in serum and acute coronary syndrome or stable angina pectoris. J Zhejiang Univ Sci B 2007; 8(12): 875-80.
  14. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354(6): 610-21.
  15. George SJ, Johnson J. Atherosclerosis: Molecular and Cellular Mechanisms. Hoboken, NJ: John Wiley & Sons; 2010.
  16. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005; 174(9): 5789-95.
  17. Jung HS, Park KH, Cho YM, Chung SS, Cho HJ, Cho SY, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 2006; 69(1): 76-85.
  18. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309(2): 286-90.
  19. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK, et al. The potential role of resistin in atherogenesis. Atherosclerosis 2005; 182(2): 241-8.
  20. Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: A new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004; 314(2): 415-9.
  21. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300(2): 472-6.
  22. Yang RZ, Huang Q, Xu A, McLenithan JC, Eisen JA, Shuldiner AR, et al. Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 2003; 310(3): 927-35.
  23. Fruhbeck G, Salvador J. Role of adipocytokines in metabolism and disease. Nutr Res 2004; 24(10): 803-26.
  24. Li R, Chen LZ, Zhao SP, Huang XS. Inflammation Activation Contributes to Adipokine Imbalance in Patients with Acute Coronary Syndrome. PLoS One 2016; 11(3): e0151916.
  25. Darabi F, Aghaei M, Movahedian A, Elahifar A, Pourmoghadas A, Sarrafzadegan N. Association of serum microRNA-21 levels with Visfatin, inflammation, and acute coronary syndromes. Heart Vessels 2017; 32(5): 549-57.
  26. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review. JAMA 1997; 278(23): 2093-8.
  27. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DP, Teepen H, van der Wal AC, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000; 150(2): 245-53.
  28. Unal I. Defining an Optimal Cut-Point Value in ROC Analysis: An Alternative Approach. Comput Math Methods Med 2017; 2017: 3762651.
  29. Kotani T, Takeuchi T, Takai S, Yoshida S, Hata K, Nagai K, et al. Serum levels of matrix metalloproteinase (MMP) 9, a risk factor for acute coronary syndrome, are reduced independently of serum MMP-3 by anti-TNF-alpha antibody (infliximab) therapy in patients with rheumatoid arthritis. J Pharmacol Sci 2012; 120(1): 50-3.
  30. Anzai A, Maekawa Y, Kodaira M, Mogi S, Arai T, Kawakami T, et al. Prognostic implications of optimal medical therapy in patients undergoing percutaneous coronary intervention for acute coronary syndrome in octogenarians. Heart Vessels 2015; 30(2): 186-92.
  31. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32(9): 2045-51.
  32. Madrigal-Matute J, Rotllan N, Aranda JF, Fernandez-Hernando C. MicroRNAs and atherosclerosis. Curr Atheroscler Rep 2013; 15(5): 322.
  33. Lendon CL, Davies MJ, Born GV, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 1991; 87(1): 87-90.
  34. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90(2): 775-8.
  35. DeClercq V, Taylor C, Zahradka P. Adipose tissue: The link between obesity and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets 2008; 8(3): 228-37.
  36. Modi KA, Nylk TM, Sheridan FM. Medical management of acute ST elevation myocardial infarction. J La State Med Soc 2001; 153(6):
  37. -90.
  38. Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, et al. Resistin promotes endothelial cell activation: Further evidence of adipokine-endothelial interaction. Circulation 2003; 108(6): 736-40.
  39. Komorowski J, Pasieka Z, Jankiewicz-Wika J, Stepien H. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid 2002; 12(8): 655-62.
  40. Ashok BT, Ali R. The aging paradox: free radical theory of aging. Exp Gerontol 1999; 34(3): 293-303.
  41. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97.
  42. Bauvois B. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012; 1825(1): 29-36.
  43. Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol 2011; 3(12).
  44. Chen CC, Li TC, Li CI, Liu CS, Wang HJ, Lin CC. serum resistin level among healthy subjects: Relationship to anthropometric and metabolic parameters. Metabolism 2005; 54(4): 471-5.
  45. Bednarska-Makaruk M, Graban A, Wisniewska A, Lojkowska W, Bochynska A, Gugala-Iwaniuk M, et al. Association of adiponectin, leptin and resistin with inflammatory markers and obesity in Dementia. Biogerontology 2017; 18(4): 561-80.
  46. He L, Hannon GJ. MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5(7): 522-31.
  47. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75(5): 855-62.
  48. Rao V, Kiran R. Evaluation of correlation between oxidative stress and abnormal lipid profile in coronary artery disease. J Cardiovasc Dis Res. 2011;2(1):57-60
ARYA Atherosclerosis Journal
Volume 16, Issue 2 - Serial Number 2
March and April 2020
Pages 46-54

Home

Guide for Authors

Submit Manuscript

Reviewers

Contact Us